CARLSBAD, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended March 31, 2026, and recent corporate updates. Three Months Ended March 31, 2026 2025Unaudited. In thousands, except ASP data. Revenue $17,306 $15,498 Gross margin 59.0% 58.9%Operating expenses $13,619 $12,488 Operating loss $(3,414) $(3,365)Net loss $(3,967) $(3,752)Adjusted EBITDA $(2,160) $(2,508)Trailing-twelve-month average selling price (ASP) $444 $419 Cash and cash equivalents $21,513 $11,194 First Quarter 2026 Highlights: Achieved record total revenue of $17.3 million, an increas